Tag Archives: Natural Killer Cells

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic

Cytovia Therapeutics, Inc. has announced today that it has licensed from ProteoNic BV its 2G UNicâ„¢ technology for boosting recombinant protein production, allowing for cost-effective manufacturing at large scale. Under the agreement, Cytovia gains non-exclusive, worldwide commercial rights for application of the technology to the development of a number of its proprietary NK Engager multifunctional antibodies.
[Cytovia Therapeutics (GlobeNewswire Inc.)]
Press Release

Continue reading “Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic”

Bookmark

No account yet? Register

0
Share

Allogeneic Stem Cell Transplantation for Patients with Aggressive NK-Cell Leukemia

Using the Japanese transplant registry data, the outcomes of 59 aggressive NK-cell leukemia patients who underwent first allogeneic hematopoietic stem cell transplantation were analyzed. Twenty-nine patients received stem cells from cord blood, 18 from peripheral blood, and 12 from bone marrow.
[Bone Marrow Transplantation]
Fujimoto, A., Ishida, F., Izutsu, K., Yamasaki, S., Chihara, D., Suzumiya, J., Mitsui, T., Doki, N., Sakai, H., Kobayashi, H., Kanda, J., Fukuda, T., Atsuta, Y., & Suzuki, R. (2020). Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplantation, 1–10. https://doi.org/10.1038/s41409-020-01009-8 Cite
Abstract

Continue reading “Allogeneic Stem Cell Transplantation for Patients with Aggressive NK-Cell Leukemia”

Bookmark

No account yet? Register

0
Share

Celularity Announces the Activation of First California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19

Celularity announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer cells for the treatment of adults with COVID-19.
[Celularity Inc.]
Press Release

Continue reading “Celularity Announces the Activation of First California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19”

Bookmark

No account yet? Register

0
Share

A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients with Classical Hodgkin Lymphoma

Investigators utilized the complementary approaches of T cell receptor sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 Phase II clinical trial
[Nature Medicine]
Cader, F. Z., Hu, X., Goh, W. L., Wienand, K., Ouyang, J., Mandato, E., Redd, R., Lawton, L. N., Chen, P.-H., Weirather, J. L., Schackmann, R. C. J., Li, B., Ma, W., Armand, P., Rodig, S. J., Neuberg, D., Liu, X. S., & Shipp, M. A. (2020). A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 1–12. https://doi.org/10.1038/s41591-020-1006-1 Cite
Abstract

Continue reading “A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients with Classical Hodgkin Lymphoma”

Bookmark

No account yet? Register

0
Share

Novel Multiparameter Correlates of Coxiella burnetii Infection and Vaccination Identified by Longitudinal Deep Immune Profiling

Using a vaccine-challenge model in HLA-DR transgenic mice, investigators demonstrated significant alterations in circulating T-cell and innate immune populations that distinguished vaccinated from naïve mice within ten days, and persisted until at least 35 days post-vaccination.
[Scientific Reports]
Reeves, P. M., Raju Paul, S., Baeten, L., Korek, S. E., Yi, Y., Hess, J., Sobell, D., Scholzen, A., Garritsen, A., De Groot, A. S., Moise, L., Brauns, T., Bowen, R., Sluder, A. E., & Poznansky, M. C. (2020). Novel multiparameter correlates of Coxiella burnetii infection and vaccination identified by longitudinal deep immune profiling. Scientific Reports, 10(1), 13311. https://doi.org/10.1038/s41598-020-69327-x Cite
Full Article

Continue reading “Novel Multiparameter Correlates of Coxiella burnetii Infection and Vaccination Identified by Longitudinal Deep Immune Profiling”

Bookmark

No account yet? Register

0
Share

Myeloid-Derived Suppressor Cell Depletion Therapy Targets IL-17A-Expressing Mammary Carcinomas

Investigators report here that IL-17A mRNA and protein were detectable in some human triple-negative breast cancer cell lines and further upregulated by IL-23 and LPS stimulation.
[Scientific Reports]
Dawod, B., Liu, J., Gebremeskel, S., Yan, C., Sappong, A., Johnston, B., Hoskin, D. W., Marshall, J. S., & Wang, J. (2020). Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas. Scientific Reports, 10(1), 13343. https://doi.org/10.1038/s41598-020-70231-7 Cite
Full Article

Continue reading “Myeloid-Derived Suppressor Cell Depletion Therapy Targets IL-17A-Expressing Mammary Carcinomas”

Bookmark

No account yet? Register

0
Share

Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T- and NK-Cell Neoplasms in the Kyoto Stem Cell Transplantation Group

39 patients received bone marrow or peripheral blood stem cell transplantation from related donors, 37 received BMT/PBSCT from unrelated donors, and 35 received cord blood transplantation
[Biology of Blood and Marrow Transplantation]
Watanabe, M., Kanda, J., Arai, Y., Hishizawa, M., Nishikori, M., Ishikawa, T., Imada, K., Ueda, Y., Akasaka, T., Yonezawa, A., Nohgawa, M., Kitano, T., Itoh, M., Takeoka, T., Moriguchi, T., Yago, K., Arima, N., Anzai, N., Watanabe, M., … Takaori-Kondo, A. (2020). Impact of donor source on allogeneic hematopoietic stem cell transplantation for mature T- and NK-cell neoplasms in the Kyoto Stem Cell Transplantation Group. Biology of Blood and Marrow Transplantation, 0(0). https://doi.org/10.1016/j.bbmt.2020.07.032 Cite
Abstract

Continue reading “Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T- and NK-Cell Neoplasms in the Kyoto Stem Cell Transplantation Group”

Bookmark

No account yet? Register

0
Share

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-Targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors

Cytovia Therapeutics, Inc announced that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR dual-targeting CAR to be used for NK cell therapy.
[Cytovia Therapeutics, Inc. (GlobeNewswire, Inc.)]
Press Release

Continue reading “Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-Targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors”

Bookmark

No account yet? Register

0
Share

Treatment of Mice with S4B6 IL-2 Complex Prevents Lethal Toxoplasmosis via IL-12- and IL-18-Dependent Interferon-Gamma Production by Non-CD4 Immune Cells

Scientists investigated the in vivo regulation of IFN-γ production by CD8+ T cells, DN T cells and NK cells in response to acute Toxoplasma gondii infection.
[Scientific Reports]
Kupz, A., Pai, S., Giacomin, P. R., Whan, J. A., Walker, R. A., Hammoudi, P.-M., Smith, N. C., & Miller, C. M. (2020). Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12- and IL-18-dependent interferon-gamma production by non-CD4 immune cells. Scientific Reports, 10(1), 13115. https://doi.org/10.1038/s41598-020-70102-1 Cite
Full Article

Continue reading “Treatment of Mice with S4B6 IL-2 Complex Prevents Lethal Toxoplasmosis via IL-12- and IL-18-Dependent Interferon-Gamma Production by Non-CD4 Immune Cells”

Bookmark

No account yet? Register

0
Share

Induced Pluripotent Stem Cell-Derived Natural Killer Cells Gene-Modified to Express Chimeric Antigen Receptor-Targeting Solid Tumors

Scientists describe the characteristics of natural killer (NK) cells from multiple cell sources, including PSCs, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells.
[International Journal of Hematology]
Abstract

Continue reading “Induced Pluripotent Stem Cell-Derived Natural Killer Cells Gene-Modified to Express Chimeric Antigen Receptor-Targeting Solid Tumors”

Bookmark

No account yet? Register

0
Share

Induced Pluripotent Stem Cell-Derived Natural Killer Cells Gene-Modified to Express Chimeric Antigen Receptor-Targeting Solid Tumors

Scientists describe the characteristics of natural killer (NK) cells from multiple cell sources, including PSCs, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells.
[International Journal of Hematology]
Abstract

Continue reading “Induced Pluripotent Stem Cell-Derived Natural Killer Cells Gene-Modified to Express Chimeric Antigen Receptor-Targeting Solid Tumors”

Bookmark

No account yet? Register

0
Share

Control of Viral Infection by Natural Killer Cell Inhibitory Receptors

Investigators showed MHC-I-restricted control of murine cytomegalovirus (MCMV) infection in vivo that was NK cell dependent. Using mice lacking specific Ly49 receptors, they showed that control of MCMV required inhibitory Ly49 receptors and an inhibitory signaling motif and the capacity for MCMV to downregulate MHC-I.
[Cell Reports]
Parikh, B. A., Bern, M. D., Piersma, S. J., Yang, L., Beckman, D. L., Poursine-Laurent, J., Plougastel-Douglas, B., & Yokoyama, W. M. (2020). Control of Viral Infection by Natural Killer Cell Inhibitory Receptors. Cell Reports, 32(4). https://doi.org/10.1016/j.celrep.2020.107969 Cite
Full ArticleGraphical Abstract

Continue reading “Control of Viral Infection by Natural Killer Cell Inhibitory Receptors”

Bookmark

No account yet? Register

0
Share
Share